<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04290429</url>
  </required_header>
  <id_info>
    <org_study_id>GLP-2 in GVHD</org_study_id>
    <nct_id>NCT04290429</nct_id>
  </id_info>
  <brief_title>Treatment of Patients With Teduglutide (GLP-2) for GVHD and Analysis of Paneth Cells of GVHD Patients</brief_title>
  <official_title>Analysis of the Effect of Teduglutide Treatment on Intestinal Malabsorption and Paneth Cell Numbers in Patients With Steroid-refractory Gastrointestinal Graft Versus Host Disease (SR-GI-GVHD).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Freiburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Freiburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators evaluate the outcomes of six steroid-refractory GVHD patients
      with gastrointestinal signs of GVHD that were treated with teduglutide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preliminary studies have showed that Glucagon-like peptide 2 (GLP-2) has regenerative and
      protective effects on the gastrointestinal tract after bowel injury. It induces positive
      effects in the GI tract like nutrient uptake, mucosal growth, protection from inflammation,
      etc. One of the target organs from GVHD is the GI tract, and since patients suffering from
      GI-GVHD experience intestinal disorders like loss of mucosal epithelial integrity, diarrhea
      accompanied by strong abdominal pain that can lead to food inanition, the investigators
      therefore aimed to examine the outcome of patients suffering from SR-GI-GVHD that are treated
      with the GLP-2 analogue, Teduglutide. The investigators will determine the outcome of each
      patient by monitoring the gastrointestinal signs like diarrhea frequency, intestinal
      absorption measured by serum-albumin concentrations and GI histology, specifically the number
      of Paneth cells before and during teduglutide treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 6, 2017</start_date>
  <completion_date type="Actual">December 6, 2019</completion_date>
  <primary_completion_date type="Actual">December 6, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Paneth cell numbers</measure>
    <time_frame>2 years</time_frame>
    <description>Quantification of Paneth cell numbers within the intestinal crypts before and during teduglutide treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stool frequency</measure>
    <time_frame>2 years</time_frame>
    <description>Analysis of patient's stool frequency before and during teduglutide treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal absorption</measure>
    <time_frame>2 years</time_frame>
    <description>Analysis of patient's albumin serum levels before and during teduglutide treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>SR-GI-GVHD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Analysis of patient's stool frequency, albumin serum levels and quantification of Paneth cell numbers in GI biopsies before and during teduglutide treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teduglutide</intervention_name>
    <description>Treatment of patients with SR-GI-GVHD with teduglutide</description>
    <arm_group_label>SR-GI-GVHD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with signs of acute SR-GI-GVHD

          -  Age ≥ 18 years

          -  Peripheral blood and stool samples available before and during treatment

          -  Written informed consent

          -  Ability to understand the nature of the study and the study related procedures and to
             comply with them

        Exclusion Criteria:

          -  Age ≤ 18 years

          -  Lack of informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Zeiser, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Center University of Freiburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Center University of Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Zeiser R, Blazar BR. Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy. N Engl J Med. 2017 Nov 30;377(22):2167-2179. doi: 10.1056/NEJMra1609337. Review.</citation>
    <PMID>29171820</PMID>
  </reference>
  <reference>
    <citation>Drucker DJ, Yusta B. Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annu Rev Physiol. 2014;76:561-83. doi: 10.1146/annurev-physiol-021113-170317. Epub 2013 Oct 25. Review.</citation>
    <PMID>24161075</PMID>
  </reference>
  <reference>
    <citation>Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7911-6.</citation>
    <PMID>8755576</PMID>
  </reference>
  <reference>
    <citation>Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res. 2001 Jan 15;61(2):687-93.</citation>
    <PMID>11212269</PMID>
  </reference>
  <reference>
    <citation>Jeppesen PB, Hartmann B, Thulesen J, Graff J, Lohmann J, Hansen BS, Tofteng F, Poulsen SS, Madsen JL, Holst JJ, Mortensen PB. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology. 2001 Mar;120(4):806-15.</citation>
    <PMID>11231933</PMID>
  </reference>
  <reference>
    <citation>Jeppesen PB, Pertkiewicz M, Messing B, Iyer K, Seidner DL, O'keefe SJ, Forbes A, Heinze H, Joelsson B. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology. 2012 Dec;143(6):1473-1481.e3. doi: 10.1053/j.gastro.2012.09.007. Epub 2012 Sep 11.</citation>
    <PMID>22982184</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 26, 2020</study_first_submitted>
  <study_first_submitted_qc>February 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2020</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Freiburg</investigator_affiliation>
    <investigator_full_name>Robert Zeiser</investigator_full_name>
    <investigator_title>Director of the Division of Tumor Immunology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teduglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

